U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C4H6N4O3
Molecular Weight 158.1154
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of Allantoin

SMILES

NC(=O)NC1NC(=O)NC1=O

InChI

InChIKey=POJWUDADGALRAB-UHFFFAOYSA-N
InChI=1S/C4H6N4O3/c5-3(10)6-1-2(9)8-4(11)7-1/h1H,(H3,5,6,10)(H2,7,8,9,11)

HIDE SMILES / InChI

Molecular Formula C4H6N4O3
Molecular Weight 158.1154
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Aldioxa is the generic name for the metal complex, dihydroxyaluminum allantoinate, which is hydrolyzed to allantoin and aluminium hydrate at the gastric mucosa. Aldioxa was approved in Japan to improve subjective symptoms or objective of gastric/duodenal ulcer and gastritis. It was discovered, that aldioxa ameliorates delayed gastric emptying through its antagonistic activity on the α-2 adrenergic receptor. The most commonly reported adverse reactions include constipation.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
BODYGLIDE FOR HER

Approved Use

helps prevent and helps relieve chafed, chapped or cracked skin. helps protect from the drying effects of wind and cold weather. temporarily protects minor cuts, scrapes, burns.

Launch Date

2009
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

protects gastric / duodenal tissue mucosa and helps repair, thus improving gastric / duodenal ulcer and gastritis. It is usually used to improve subjective symptoms or objective of gastric/duodenal ulcer and gastritis.
Primary
Unknown

Approved Use

protects gastric / duodenal tissue mucosa and helps repair, thus improving gastric / duodenal ulcer and gastritis. It is usually used to improve subjective symptoms or objective of gastric/duodenal ulcer and gastritis.
Primary
Unknown

Approved Use

protects gastric / duodenal tissue mucosa and helps repair, thus improving gastric / duodenal ulcer and gastritis. It is usually used to improve subjective symptoms or objective of gastric/duodenal ulcer and gastritis.
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
6.43 μg/mL
10 mg/kg 3 times / day steady-state, oral
dose: 10 mg/kg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ALLANTOIN plasma
Canis lupus
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
30 μg × h/mL
10 mg/kg 3 times / day steady-state, oral
dose: 10 mg/kg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ALLANTOIN plasma
Canis lupus
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
2.69 h
10 mg/kg 3 times / day steady-state, oral
dose: 10 mg/kg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ALLANTOIN plasma
Canis lupus
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
PubMed

PubMed

TitleDatePubMed
[Pharmacological study of dihydroxyaluminum allantoinate and chlorhydroxyaluminum allantoinate. I. Toxicity].
1962 Jul-Aug
[Evaluation of the anti-ulcer drugs using image analysis technology: effect of aldioxa containing preparation on the experimental gastric ulcer in rats].
1989 Nov
[The effect of aldioxa on the formation of gastritis induced with sodium hydroxide].
1990 Nov
[Acidified aspirin-induced gastric lesion in rats with hepatic cirrhosis produced by N-nitrosodiethylamine or carbon tetrachloride. Effect of aldioxa on gastric lesions].
1994 Mar
Aldioxa improves delayed gastric emptying and impaired gastric compliance, pathophysiologic mechanisms of functional dyspepsia.
2015 Dec 1

Sample Use Guides

In Vivo Use Guide
Sources: file:///C:/Users/Mark/Desktop/info_20ALCLOXA.pdf
Antiperspirants, deodorants: Creams, spray, lossions: 0.25-0.5% Baby products: creams; powders: 0.2-0.5%
Route of Administration: Topical
In Vitro Use Guide
Sources: file:///C:/Users/Mark/Desktop/info_20ALCLOXA.pdf
In vitro Alcloxa inhibited formation and bacterial decomposition of pulverized human epidermal scales. The scales were obtained from patient with exfoliative dermatitis, characterized by a great deal of exudation. The scales were were pulverized in a Wiley mill, defatted with ether and suspended in a 0,2% Alcloxa solution.
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:35:52 GMT 2023
Edited
by admin
on Fri Dec 15 16:35:52 GMT 2023
Record UNII
344S277G0Z
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
Allantoin
EP   HSDB   II   INCI   JAN   MART.   MI   USAN   USP   USP-RS   VANDF   WHO-DD  
INCI   USAN  
Official Name English
IDELALISIB METABOLITE M1A
Common Name English
ALLANTOIN [INCI]
Common Name English
ALLANTOIN [USP MONOGRAPH]
Common Name English
CORDIANINE
Common Name English
NSC-7606
Code English
PSORALON
Common Name English
Allantoin [WHO-DD]
Common Name English
ALWEXTIN
Brand Name English
ALLANTOIN [MART.]
Common Name English
(2,5-DIOXO-4-IMIDAZOLIDINYL)UREA
Systematic Name English
ALLANTOIN [HSDB]
Common Name English
ALLANTOIN [VANDF]
Common Name English
SD 101 [WHO-DD]
Common Name English
(±)-ALLANTOIN
Common Name English
ALLANTOIN [II]
Common Name English
ALLANTOIN [MI]
Common Name English
ALLANTOIN [JAN]
Common Name English
UREA, (2,5-DIOXO-4-IMIDAZOLIDINYL)-
Systematic Name English
ALLANTOIN [USAN]
Common Name English
5-UREIDOHYDANTOIN
Systematic Name English
DL-ALLANTOIN
Common Name English
SEPTALAN
Common Name English
ALLANTOIN [USP-RS]
Common Name English
ALLANTOIN [EP MONOGRAPH]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C29700
Created by admin on Fri Dec 15 16:35:52 GMT 2023 , Edited by admin on Fri Dec 15 16:35:52 GMT 2023
CFR 21 CFR 347.10
Created by admin on Fri Dec 15 16:35:52 GMT 2023 , Edited by admin on Fri Dec 15 16:35:52 GMT 2023
FDA ORPHAN DRUG 151001
Created by admin on Fri Dec 15 16:35:52 GMT 2023 , Edited by admin on Fri Dec 15 16:35:52 GMT 2023
DSLD 3892 (Number of products:4)
Created by admin on Fri Dec 15 16:35:52 GMT 2023 , Edited by admin on Fri Dec 15 16:35:52 GMT 2023
CFR 21 CFR 310.534
Created by admin on Fri Dec 15 16:35:52 GMT 2023 , Edited by admin on Fri Dec 15 16:35:52 GMT 2023
EU-Orphan Drug EU/3/13/1232
Created by admin on Fri Dec 15 16:35:52 GMT 2023 , Edited by admin on Fri Dec 15 16:35:52 GMT 2023
NCI_THESAURUS C29708
Created by admin on Fri Dec 15 16:35:52 GMT 2023 , Edited by admin on Fri Dec 15 16:35:52 GMT 2023
EPA PESTICIDE CODE 85701
Created by admin on Fri Dec 15 16:35:52 GMT 2023 , Edited by admin on Fri Dec 15 16:35:52 GMT 2023
Code System Code Type Description
DRUG BANK
DB11100
Created by admin on Fri Dec 15 16:35:52 GMT 2023 , Edited by admin on Fri Dec 15 16:35:52 GMT 2023
PRIMARY
DRUG CENTRAL
4268
Created by admin on Fri Dec 15 16:35:52 GMT 2023 , Edited by admin on Fri Dec 15 16:35:52 GMT 2023
PRIMARY
NCI_THESAURUS
C74277
Created by admin on Fri Dec 15 16:35:52 GMT 2023 , Edited by admin on Fri Dec 15 16:35:52 GMT 2023
PRIMARY
HSDB
7490
Created by admin on Fri Dec 15 16:35:52 GMT 2023 , Edited by admin on Fri Dec 15 16:35:52 GMT 2023
PRIMARY
WIKIPEDIA
ALLANTOIN
Created by admin on Fri Dec 15 16:35:52 GMT 2023 , Edited by admin on Fri Dec 15 16:35:52 GMT 2023
PRIMARY
RS_ITEM_NUM
1012939
Created by admin on Fri Dec 15 16:35:52 GMT 2023 , Edited by admin on Fri Dec 15 16:35:52 GMT 2023
PRIMARY
EPA CompTox
DTXSID3020043
Created by admin on Fri Dec 15 16:35:52 GMT 2023 , Edited by admin on Fri Dec 15 16:35:52 GMT 2023
PRIMARY
ECHA (EC/EINECS)
202-592-8
Created by admin on Fri Dec 15 16:35:52 GMT 2023 , Edited by admin on Fri Dec 15 16:35:52 GMT 2023
PRIMARY
FDA UNII
344S277G0Z
Created by admin on Fri Dec 15 16:35:52 GMT 2023 , Edited by admin on Fri Dec 15 16:35:52 GMT 2023
PRIMARY
EVMPD
SUB12779MIG
Created by admin on Fri Dec 15 16:35:52 GMT 2023 , Edited by admin on Fri Dec 15 16:35:52 GMT 2023
PRIMARY
ChEMBL
CHEMBL593429
Created by admin on Fri Dec 15 16:35:52 GMT 2023 , Edited by admin on Fri Dec 15 16:35:52 GMT 2023
PRIMARY
PUBCHEM
204
Created by admin on Fri Dec 15 16:35:52 GMT 2023 , Edited by admin on Fri Dec 15 16:35:52 GMT 2023
PRIMARY
CAS
97-59-6
Created by admin on Fri Dec 15 16:35:52 GMT 2023 , Edited by admin on Fri Dec 15 16:35:52 GMT 2023
PRIMARY
MERCK INDEX
m1520
Created by admin on Fri Dec 15 16:35:52 GMT 2023 , Edited by admin on Fri Dec 15 16:35:52 GMT 2023
PRIMARY Merck Index
NSC
7606
Created by admin on Fri Dec 15 16:35:52 GMT 2023 , Edited by admin on Fri Dec 15 16:35:52 GMT 2023
PRIMARY
MESH
D000481
Created by admin on Fri Dec 15 16:35:52 GMT 2023 , Edited by admin on Fri Dec 15 16:35:52 GMT 2023
PRIMARY
DAILYMED
344S277G0Z
Created by admin on Fri Dec 15 16:35:52 GMT 2023 , Edited by admin on Fri Dec 15 16:35:52 GMT 2023
PRIMARY
SMS_ID
100000078014
Created by admin on Fri Dec 15 16:35:52 GMT 2023 , Edited by admin on Fri Dec 15 16:35:52 GMT 2023
PRIMARY
CHEBI
15676
Created by admin on Fri Dec 15 16:35:52 GMT 2023 , Edited by admin on Fri Dec 15 16:35:52 GMT 2023
PRIMARY
RXCUI
508
Created by admin on Fri Dec 15 16:35:52 GMT 2023 , Edited by admin on Fri Dec 15 16:35:52 GMT 2023
PRIMARY RxNorm
Related Record Type Details
PARENT -> CONSTITUENT ALWAYS PRESENT
PARENT -> CONSTITUENT ALWAYS PRESENT
Related Record Type Details
PARENT -> METABOLITE
PARENT -> METABOLITE
PARENT -> METABOLITE
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (TLC)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (TLC)
EP
Related Record Type Details
ACTIVE MOIETY